By Josh Beckerman
Biohaven shares slipped after the Food and Drug Administration extended the Prescription Drug User Fee Act date for the biopharmaceutical company's troriluzole application by three months.
The stock was down 8.5%, to $17.99, after hours Wednesday and has dropped about 47% since the start of the year.
The FDA's Division of Neurology 1 also informed the New Haven, Conn., company that it plans to hold an advisory committee meeting, but no date has been scheduled. The FDA didn't raise any new concerns in its letter.
Biohaven now expects an FDA decision in the fourth quarter.
Troriluzole is a potential treatment for spinocerebellar ataxia, a group of inherited neurodegenerative disorders.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 14, 2025 19:10 ET (23:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。